Major depressive disorder Depression Folic acid Methylcobalamin Fluoxetine BDNF Cognitive function Antidepressants Neuroplasticity SSRI Vitamin B12
Conditions
Interventions
Patients in this group will receive standard fluoxetine therapy (20 mg/day) combined with oral folic acid 1 mg/day and methylcobalamin 500 mcg/day for 6 weeks.,Patients in this group will receive stan
Experimental Drug,Active Comparator Drug
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
20 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Adults aged between 20 and 45 years. 2. Diagnosed with depression based on PPDGJ-III criteria. 3. Currently undergoing treatment with fluoxetine. 4. Minimum education level of junior high school. 5. Willing to participate by providing informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with psychiatric disorders due to organic causes. 2. History of substance abuse within the past year. 3. Presence of chronic illnesses requiring the use of anti-inflammatory drugs, antibiotics, or other supplements. 4. Experiencing severe psychiatric symptoms, such as psychosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum Brain-Derived Neurotrophic Factor (BDNF) level Baseline and 6 weeks after intervention Measured using ELISA from serum samples,Cognitive function score Baseline and 6 weeks after intervention Assessed using Montreal Cognitive Assessment Indonesian Version (MoCA-Ina) | — |
Secondary
| Measure | Time frame |
|---|---|
| Depression severity score Baseline and 6 weeks after intervention Measured using a standardized depression scale (e.g. Hamilton Depression Rating Scale or equivalent),Adverse events Throughout the 6-week study period Monitored by clinician during scheduled visits and patient self-reporting | — |
Countries
Indonesia
Contacts
Public ContactMaria Dianomo
Hasanuddin University
Outcome results
None listed